Michael Gollin is a patent attorney who has pioneered intellectual property strategies that help clients put their ideas to work. He chairs the Life Sciences group, and has more than two decades' experience in intellectual property law and related areas including technology transfer, food, drug, and cosmetics law, and environmental law. He focuses on strategic counseling and IP monetization. He builds teams that prosecute patents and trademarks, negotiate intellectual property agreements, and litigate patent, trademark, copyright, and trade secret cases.
Mr. Gollin represents biotechnology and pharmaceutical companies, among others -- from start ups through emerging-growth companies to multinational publicly traded companies. He also represents leading research institutions including UCLA and the J. Craig Venter Institute.
Mr. Gollin has built and managed worldwide intellectual property portfolios of hundreds of patents and trademarks, conducted due diligence and intellectual property audits for mergers, acquisitions, and investment rounds, and has negotiated hundreds of licenses and other agreements.
His litigation and dispute resolution experience includes a successful appeal of a pharmaceutical patent decision to the Federal Circuit, dismissal of a patent suit against a client, revocation of a competitor's European patent, and prevailing in a trademark lawsuit and oppositions, including extensive discovery, briefing, and settlement negotiations. He has recently filed amicus briefs at the Supreme Court and Federal Circuit and handled a petition for certiorari.
Mr. Gollin has provided countless complex formal opinions regarding patent infringement and validity, including a set of five opinions for 10 separate companies. He also conducted the first intellectual property audits of five International Agricultural Research Centers on five continents.
Mr. Gollin built a robust patent portfolio for a medical device company that was sold for over $30 million. Mr. Gollin has negotiated many complex technology transfer agreements, including patent licenses, a bioinformatics subscription by Novartis, a biochip license from Affymetrix, a domain name purchase, and biodiversity access for biotechnology research based on plants obtained from Panama, Fiji, and Central Africa.
He has handled inventorship disputes with corporations, universities, federal agencies, and in interference proceedings.
Mr. Gollin is an adjunct professor at Georgetown University's McDonough School of Business, where he created the Strategic Management of Intellectual Property course.
He is also an adjunct professor at Franklin Pierce Center for Intellectual Property at the University of New Hampshire School of Law, where he teaches Global Intellectual Property Management.
In 2002, he launched Public Interest Intellectual Property Advisors (PIIPA), a pro bono service for developing country clients, with Venable support.
Mr. Gollin is working to accelerate amyotrophic lateral sclerosis (ALS) research through his pro bono representation of the Muscular Dystrophy Association (MDA) and his work with the ALS Association.